Rocket Pharmaceuticals: Pay

Rocket Pharmaceuticals paid its 2 named executives $7.1M in total in FY2025 (Dec). CEO Gaurav D. Shah, M.D. was paid $3.5M of that.

Pay$100 in the stock at the end of FY20 → $6
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Christopher StevensChief Operating Officer
FY2025 (Dec)
1 year
Gaurav D. Shah, M.D.Chief Executive Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years

CEO pay against the pay peers

In FY2023 (Dec), the median CEO pay of the 3 peers with pay on file was $5.9M. The CEO of Rocket Pharmaceuticals was paid $8.0M, 35% above the median.

  1. 1Rocket Pharmaceuticals
  2. 2Beam Therapeutics
  3. 3Regenxbio
  4. 4Replimune Group
  5. 5AgiosNot disclosed
  6. 6AllogeneNot disclosed
  7. 7AmicusNot disclosed
  8. 8Bluebird bioNot disclosed
  9. 9BridgeBioNot disclosed
  10. 10CRISPR AGNot disclosed
  11. 11EditasNot disclosed
  12. 12IntelliaNot disclosed
  13. 13KrystalNot disclosed
  14. 14MiratiNot disclosed
  15. 15RhythmNot disclosed
  16. 16TenayaNot disclosed
  17. 17UltragenyxNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.